Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03396328
Other study ID # 4-2017-0906
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 10, 2018
Est. completion date May 12, 2020

Study information

Verified date September 2020
Source Yonsei University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Albuminuria is a known risk factor for cardiovascular disease (CVD), chronic kidney disease (CKD) progression, all cause mortality. Inhibition of the renin-angiotension-aldosterone system (RAAS) plays an important role in the reduction of albuminuria and preservation of renal function in patients with CKD and it is known that the daily intakes of sodium have a significant effect on the activity of RAAS. Dietary sodium restriction has been shown to enhances the blood pressure, albuminuria, and renal function preservation. Furthermore, recent study has shown that intensive low-salt dietary education reduces albuminuria in patients with CKD. The average sodium intake of Koreans is 4,791 mg/d, which is higher than other countries. It is difficult for medical staff in Korea to invest enough time in low salt diet.

Recently, the development of health-related applications (apps) has been carried out worldwidely, and researches on lifestyle improvement using apps have been actively studied. However, there is no research yet on whether intensive education using an apps can affect lifestyle habits and thus changes in actual new features. Smartphone apps may provide an alternative to resource-intensive low salt diet-education. Therefore, this study aims to investigate the effect of intensive low salt diet training on the changes of albuminuria using application.


Description:

This is an pen-label, case-control, randomized clinical trial.

- Run-in period (8 weeks) : before 8 weeks of study initiation, all of the patients have to stop all RAAS blockers or diuretics and switch to antihypertensive agents of other categories such as calcium channel blockers.

- 0-8 weeks : After run-in period, the patients complete laboratory examination and a dish frequency questionnaire. From 0 weeks, all participants will be prescribed valsartan 80mg per day until the end of study.

- 8-16 weeks : After 8 weeks, the patients will be randomly assigned to receive an low-salt dietary intervention after second laboratory examination.

Usual education : Conventional education at an outpatient clinic Intensive education : Low salt diet education through Smartphone app

The patients in the conventional education group will receive routine CKD education once at an outpatient clinic. Otherwise, the patients in the intensive education group will be trained low salt diet through smartphone app.


Recruitment information / eligibility

Status Completed
Enrollment 108
Est. completion date May 12, 2020
Est. primary completion date May 12, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 65 Years
Eligibility Inclusion Criteria:

- Age : 19-65

- Underlying hypertension or antihypertensive medication , or Systolic blood pressure ? 140 mmHg or Diastolic blood pressure ? 90

- Modification of Diet in Renal Disease study (MDRD) eGFR ? 30 ml/min per 1.73m2

- Random urine albumin-to-creatinine ratio ? 30 mg/g

- Smartphone ownership

Exclusion Criteria:

- Age under 18 or over 66

- Uncontrolled hypertension (BP>160/110 mmHg)

- Pregnancy within 6 months

- Serum potasium > 5.5 mEq/L

- malignancy

- a diagnosis of CVD (cerebral infarction, hemorrhagic infarction, acute myocardial infarction or unstable angina, coronary angioplasty, or coronary artery bypass surgery) within the last 6 months

- Contraindication to angiotensin II receptor blocker

- life expectancy less than 6 months

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
conventional low salt education
conventional low salt education
Intensive low salt dietary education by smartphone application
Participants are provided with information on food and recipe, which allows them to record daily meals in their applications. Through the mobile application, the participants receive information on daily salt intake. Based on this information, the clinical nutritionist coach sets a goal for low salt diet and provides feedback to the patients through the mobile application. The clinical nutritionist coach checks the activity of the user more than twice a week and sends in-app messages to maintain compliance.

Locations

Country Name City State
Korea, Republic of Division of Nephrology, Department of Internal Medicine Yonsei University College of Medicine Seoul

Sponsors (1)

Lead Sponsor Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Decrements of 24-hour urine albumin levels Decrements of 24-hour urine albumin levels 12 weeks after low salt diet education 12 weeks after low salt diet education start
Secondary Decrements of 24-hour urine sodium 12 weeks after low salt diet education start
Secondary Change of blood pressure with a sphygmomanometer 12 weeks after low salt diet education start
See also
  Status Clinical Trial Phase
Completed NCT00095290 - Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria Phase 4
Completed NCT02144740 - Effect of NWT-03 on Blood Pressure N/A
Completed NCT01041599 - Correlation of Albuminuria With Arterial Stiffness N/A
Active, not recruiting NCT05321095 - Screening for Albuminuria at the First Line for Early Identification of CKD
Completed NCT02945969 - Sodium Lowering and Urinary Protein Reduction Trial Phase 3
Enrolling by invitation NCT04295889 - Towards HOMe-based Albuminuria Screening: an Implementation Study Testing Two Approaches N/A
Recruiting NCT04272359 - Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus
Completed NCT03889236 - Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy. N/A
Active, not recruiting NCT00625820 - Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria Phase 2
Recruiting NCT04752293 - Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
Completed NCT03118739 - Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria Phase 2
Completed NCT06374043 - Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. Phase 4
Not yet recruiting NCT06094920 - Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial Phase 4
Recruiting NCT00342927 - Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
Completed NCT02689778 - Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy Phase 3
Completed NCT02497300 - Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease Phase 2
Completed NCT02446548 - Influence of Aliskiren on Albuminuria After Kidney Transplantation N/A
Completed NCT01547897 - NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria Phase 2
Enrolling by invitation NCT01316068 - Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients Phase 4
Completed NCT00312780 - Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy Phase 2